Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Labachevski, BojanSubject: search.filters.subject.PAT

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with chronic myeloid leukemia treated with imatinib
    (Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, 2024-03)
    Labachevski, Bojan
    ;
    ;
    ;
    Popova Labachevska, Marija
    ;
    Antioxidant status in patients with chronic myeloid leukemia (CML) is significantly decreased in comparison with healthy individuals. Oxidative stress (OS) may be associated with the pathophysiology of CML and can influence on development of resistance to imatinib. The aim of our study was to investigate the effect of Aronia melanocarpa extract (A-lixir 400 PROTECT®) on OS in CML patients treated with imatinib. In this study a total of 40 CML patients treated with imatinib for longer than 1 month were included: twenty patients were treated with imatinib and A-Lixir 400 PROTECT® (treatment group) and twenty patients were treated only with imatinib (control group). OS parameters (d-ROM, PAT and OSI) were measured at the initial visit, and after 21 and 42 days of treatment. Adjuvant treatment with A-Lixir 400 PROTECT® could lead to attenuation of OS. d-ROM and OSI in this group of patients were significantly higher at initial visit when compared to values after 21 and 42 days of treatment (p<0.05). Total antioxidant capacity (PAT) was significantly higher after 21 and 42 days of treatment initiation in comparison with the pretreatment values. In the control group no significant differences were obtained between investigated parameters at any time of measurement. We can conclude that adjuvant treatment with A-Lixir 400 PROTECT® after 21 and 42 days lead to significant reduction of OS in patients with CML treated with imatinib.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    ASSESSMENT AND CORELATION OF OXIDATIVE STRESS BETWEEN HEALTHY ADULTS AND ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB
    (Macedonian Association of Anatomists, 2023-05-10)
    Labachevski, Bojan
    ;
    Popova Labachevska, Marija
    ;
    ;
    ;
    Reactive oxygen species (ROS) are oxygen-containing radicals essential for cell signaling and other vital physiological functions. However, their increased production to an excessive amount can cause alterations in the cellular redox status with consecutive disruption of various normal biological functions. Oxidative stress (OS) occurs when there is an imbalance between ROS production and antioxidant defence mechanisms. Chronic OS results in many DNA modifications, and alterations in DNA repair, leading to DNA lesions of which many can be toxic and/or mutagenic. It is proven that OS is involved in the pathogenesis of chronic myeloid leukaemia (CML), a myeloproliferative neoplasm characterized by uncontrolled proliferation of maturing and mature myeloid cells, caused by the presence of translocation t(9;22) leading to the abnormal BCR-ABL fusion protein. Historically treatment options for this disease were limited, with allogeneic stem cell transplant being the only potential curative therapy, but still with poor prognosis. Fortunately, the introduction of tyrosine kinase inhibitors (TKIs) changed dramatically the prognosis of CML patients, turning a once fatal disease, into a chronic and manageable disorder. Analysis of CML patients treated with TKIs revealed a potential correlation between toxic effects of TKIs and levels of ROS. Even though the innovation of this therapy has significantly improved the life expectancy CML patients, still, in some cases, this treatment becomes ineffective. In order to clarify these observations, we measured and correlated the level of oxidative stress between healthy individuals and patients with chronic myeloid leukemia (CML) treated with first generation tyrosine kinase inhibitors (TKIs).The two markers of oxidative stress, d-ROMs and OSI were significantly higher in the group of patients with CML compared to healthy subjects. No statistically significant differences were observed between CML patients and healthy subjects regarding the oxidative stress marker PAT.